LUMA Vision, maker of a 4D cardiac imaging and navigation platform that uses machine learning, announced it secured $22 million in Series A3 financing.
The round was led by existing investors ABV Uni Fund, imec.xpand and EQT Lifesciences, and included new investors Bayern Kapital, Atlantic Bridge Growth Fund and an undisclosed strategic investor.
WHAT IT DOES
LUMA, which spun out of Trinity College in Dublin, developed a cardiac-focused 4D imaging and navigation platform called VERAFEYE, which allows for real-time soft tissue imaging for ease of intracardiac and endovascular navigation.
LUMA Vision, which has offices in Dublin and Munich, plans to use the funds to procure FDA clearance in the United States for VERAFEYE, lay the groundwork for commercialization in the U.S. and further develop its platform.
“Physicians require accurate, real-time data at the point of care in order to effectively treat patients,” LUMA Vision CEO Fionn Lahart said in a statement. “Our goal with VERAFEYE is to provide the data and imaging physicians need in one system to successfully treat as many of the conditions their patients face as possible. By developing a technology platform that can be tailored for specific therapies in cardiology, we believe that VERAFEYE can be a bedrock of medical imaging for many years to come.”
Other companies offering 4D technology include GE Healthcare, which offers its Voluson i platform, a 4D compact ultrasound system for women’s healthcare, and Japanese company Canon Medical System, formerly Toshiba Medical Systems, which offers its AI-powered Alphenix 4D CT technology.